skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

医療用医薬品・医療機器産業の経営層向けニュース

In Vivo(インビボ)は主に「成長」「イノベーション」「リーダーシップ」「マーケットアクセス」「マーケットインテリジェンス」の5つの観点から世界の医療用医薬品産業のトレンドを取材しています。

世界の開発パイプラインを分析したインフォーマ・ファーマインテリジェンス発行のレポート「Pharma R&D Annual Review 2018」によると、日本は創薬能力では世界第2位、市場規模でも3位につけています。欧米の新薬創出国と比較して劣っているわけではありません。

一方で世界の大手医薬品企業の経営幹部は、激しい国際競争を勝ち抜くために最新情報を常に把握し、戦略的思考で成長の機会をうかがっています。

In Vivoを読むことによって、経営に携わる人々は根拠をもって意思決定をし、リスクをコントロールできるようになります。In Vivoは今日の経営層または新規ビジネス開発担当者にとっては必須のビジネスツールです。

経営戦略・トップマネジメントの視点から研究開発や財務戦略なども含む医薬品産業ニュースを読めるのはIn Vivoだけです。特集記事、注目の人物、KOLの独占インタビュー、業界幹部の異動情報なども充実しています。

無料トライアルをぜひご利用ください。

このサービスの特徴

無料の最新記事&レポート

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    In Vivo Personalised Medicine

    18 Sep 2019

    With more individualized treatments, such as cell and gene therapies, coming to market every day, In Vivo can keep you up to date on the diversity within clinical R&D, trials, the latest trends and the barriers that still exist within personalised medicine. We’ve pulled together a helpful infographic to summaries these changes.

    Topic personalized-medicine

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Personalised Medicine: Treating the individual patient

    17 Sep 2019

    With more individualized treatments, such as cell and gene therapies, coming to market every day, In Vivo can keep you up to date on the diversity within clinical R&D, trials, the latest trends and the barriers that still exist within personalised medicine. We’ve pulled together information covering the increasing focus of personalized medicine in clinical R&D and the future trends of precision medicine. 

    Topic personalized-medicine

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Six of the Greatest Therapeutic R&D Challenges

    23 Aug 2019

    Explore the six biggest therapeutic R&D challenges facing the industry today with a free infographic from In Vivo.  This snapshot view of the major issues facing R&D is packed with data and insights about everything from drug resistance to diagnostics challenges.  

    Topic Drug development landscape

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    In Vivo Content - Relied Upon by Senior Decision Makers

    21 Aug 2019

    There are many ways to market your brand and establish your business as a thought leader - but none of these methods compare to the distinct advantage gained through marketing with In Vivo and Informa Pharma Intelligence. The articles, news and interviews we feature are used daily by senior decision-makers to support their decisions, and to keep abreast of what their competitors are doing. 

    Topic Business strategies Medtech

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    MedTech Forum 2019: The Future Is Here But Industry Still Needs A Long-Term Vision

    By Ashley Yeo 16 Aug 2019

    MedTech Forum 2019: The Future Is Here But Industry Still Needs A Long-Term Vision

    In a world where national economies are beset by conflicting spending priorities, health care is oftentimes too low on the agenda, health care observers say. One of these is Boston Scientific senior vice-president Eric Thépaut, who understands the dilemmas, but says that health care will soon force its way up the priority list. He has advice for future-ready medtech innovators.

    Topic medtech business-strategies

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Could The Gut Cure Brain Disease?

    By Melanie Senior 08 Aug 2019

    Could The Gut Cure Brain Disease?

    Scientists now understand that there are multiple, bi-directional links between gut and brain. They are using this knowledge to develop new treatments for some of the most challenging chronic conditions, including Alzheimer’s disease, Parkinson’s disease and obesity.

    Topic diseases

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Meet the 2019 Titans of Pharma

    31 Jul 2019

    Get exclusive info on the leaders of the Pharma industry.The 2019 Titan of Pharma infographic is a snapshot of the industry’s top leaders and the businesses they oversee.

    Topic company-analysis strategy

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    How To Negotiate With Public Payers: Five Lessons - And A Few Cautions - From The UK's New Pact On Drug Price And Access

    By William Looney 30 Jul 2019

    How To Negotiate With Public Payers: Five Lessons - And A Few Cautions - From The UK's New Pact On Drug Price And Access

    In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets. 

    Topic brexit policy-and-regulation

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース, In Vivo: 医療用医薬品・医療機器産業の経営層向けニ...

    AI in the Pharmaceutical Landscape

    25 Jul 2019

    AstraZeneca’s pact with the UK-based artificial intelligence leader BenevolentAI, in April 2019, is one component in a string of recent deals that have highlighted big pharma’s desire to embed AI and machine learning within the R&D process. In total, 13 such collaborations have been tracked in the past 24 months, according to the Strategic Transactions database.

    Topic digital-health strategy medtech

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    MedTech Forum 2019: In The Medtech Glasshouse, Industry Need Not Fear Stones

    12 Jul 2019

    MedTech Forum 2019: In The Medtech Glasshouse, Industry Need Not Fear Stones

    Medtech’s contribution to health care improvements in Europe over the past 30 years has been a phenomenal journey of success – in patient terms as well as in commercial terms, says MedTech Europe chair Rob ten Hoedt. Local creativity has been able to mine a seam of product innovation that is unmatched anywhere in the world, but the sector is facing massive change and must find ways to cope.

    Topic medtech digital-health

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    New Science As A Business Growth Strategy

    By Sanskriti Thakur and Gordon Murphy 04 Jul 2019

    New Science As A Business Growth Strategy

    Finding innovative ways to adapt the biopharma business model to external and internal challenges is a key competitive differentiator for today’s C-suite leadership.

    Topic biopharmaceutical research

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Science Matters: Merck Joins Crowded NASH Race As Several Data Readouts Loom

    02 Jul 2019

    Science Matters: Merck Joins Crowded NASH Race As Several Data Readouts Loom

    No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.

    Topic clinical-trials

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

    By Mandy Jackson 02 Jul 2019

    Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

    Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.

    Topic biopharmaceutical

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    David Or Goliath: Where Is Innovation Winning Through?

    By Lucie Ellis 02 Jul 2019

    David Or Goliath: Where Is Innovation Winning Through?

    With both a big pharma and biotech leadership perspective, David Meeker talks to In Vivo about how smaller firms can more easily fly solo in drug development, challenges effecting the innovative drug development sector in 2019 and the partnering environment for cell and gene therapy companies.

    Topic biopharmaceutical drug-approval drug-development-landscape drug-review

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Clinical Trials In 2019: Is Biopharma Ready To Tackle The Iron Triangle of Time, Cost and Quality?

    By William Looney 02 Jul 2019

    Clinical Trials In 2019: Is Biopharma Ready To Tackle The Iron Triangle of Time, Cost and Quality?

    The clinical trial embodies the hope and the hassle of biopharma’s mission to develop new drugs for patients. It is an endlessly imperfect process: C-suite calls for more efficiency and speed at lower cost has been the story for decades. But an In Vivo conversation with a leading expert on trial management pinpoints three key trends that suggest better days are ahead for this central pillar of the innovation imperative.

    Topic Clinical trials

医薬品産業専門のジャーナリスト&アナリスト

Editor

William Looney

Editor, Executive Editor, In Vivo
William Looney

William specializes in

  • Biopharma pipeline strategy
  • Biotech
  • Commercial Strategy
  • Market Access
  • Policy and Regulation

+39 year(s) experience

Editor

Cathy Kelly

Editor, Senior editor

Washington DC

Cathy Kelly

無料トライアル&お問い合わせ

ニュースサービスでは無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。